Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030. Orforglipron lowered A1C by 1.3%–1.6% from baseline in Phase 3 ACHIEVE-1 trial. Historic Summer Setup: 3 "Power ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively. In addition, retatrutide is Lilly’s next-generation weight loss candidate.

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve’s innovative gene-editing technology, which permanently ...